107 related articles for article (PubMed ID: 6293640)
1. Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.
Skinner GR; Woodman CB; Hartley CE; Buchan A; Fuller A; Durham J; Synnott M; Clay JC; Melling J; Wiblin C; Wilkins J
Br J Vener Dis; 1982 Dec; 58(6):381-6. PubMed ID: 6293640
[TBL] [Abstract][Full Text] [Related]
2. Early experience with "antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis.
Skinner GR; Woodman C; Hartley C; Buchan A; Fuller A; Wiblin C; Wilkins G; Melling J
Dev Biol Stand; 1982; 52():333-44. PubMed ID: 6299842
[TBL] [Abstract][Full Text] [Related]
3. Antibody reactivity with Skinner HSV vaccine.
Muniu EM; Durham J; Shariff D; Hartley CE; Fuller A; Melling J; Wiblin C; Wilkins G; Buchan A; Skinner GR
Med Microbiol Immunol; 1987; 176(6):315-27. PubMed ID: 2828898
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of vaccine Ac NFU1 (S-) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis.
Woodman CB; Buchan A; Fuller A; Hartley C; Skinner GR; Stocker D; Sugrue D; Clay JC; Wilkins G; Wiblin C
Br J Vener Dis; 1983 Oct; 59(5):311-3. PubMed ID: 6311322
[TBL] [Abstract][Full Text] [Related]
5. The preparation, efficacy and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects.
Skinner GR; Buchan A; Hartley CE; Turner SP; Williams DR
Med Microbiol Immunol; 1980; 169(1):39-51. PubMed ID: 6258035
[TBL] [Abstract][Full Text] [Related]
6. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine.
Skinner GR; Fink CG; Cowan M; Buchan A; Fuller A; Hartley CE; Durham J; Wiblin C; Melling J
Med Microbiol Immunol; 1987; 176(3):161-8. PubMed ID: 3037289
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFUi(S-) MRC against primary type 2 herpes simplex virus infection.
Skinner GR; Buchan A; Williams D; Marsden J; Hartley C; Wilbanks G; Turyk M; Namkoong ES
Br J Exp Pathol; 1982 Aug; 63(4):378-87. PubMed ID: 6295430
[TBL] [Abstract][Full Text] [Related]
8. Prevention of type 2 herpes simplex virus induced cervical carcinoma in mice by prior immunization with a vaccine prepared from type 1 herpes simplex virus.
Chen MH; Dong CY; Liu ZH; Skinner GR; Hartley CE
Vaccine; 1983 Dec; 1(1):13-6. PubMed ID: 6099637
[TBL] [Abstract][Full Text] [Related]
9. Vaccine induced HSV 1 antibodies fail to correlate with protection against HSV 2 in guinea pigs.
Welch MJ; Ridgeway PH; Phillpotts RJ
FEMS Microbiol Immunol; 1988 Dec; 1(3):157-62. PubMed ID: 2856207
[TBL] [Abstract][Full Text] [Related]
10. The relative infrequency and low levels of neutralising and immunoprecipitating antibody to herpes simplex viruses types 1 and 2 in patients with a history of recurrent herpes genitalis.
Woodman CB; Stocker D; Sugrue D; Desberbasques M; Hartley CE; Fuller A; Buchan A; Skinner GR
Med Microbiol Immunol; 1983; 171(4):243-50. PubMed ID: 6304481
[TBL] [Abstract][Full Text] [Related]
11. A virus-particle vaccine prepared from bovine mammillitis virus against herpes genitalis.
Skinner GR; Buchan A; Davies J; Durham J; Castrucci G
Comp Immunol Microbiol Infect Dis; 1991; 14(2):133-50. PubMed ID: 1657508
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of a herpes simplex subunit vaccine.
Cappel R; Sprecher S; De Cuyper F; De Braekeleer J
J Med Virol; 1985 Jun; 16(2):137-45. PubMed ID: 2989419
[TBL] [Abstract][Full Text] [Related]
13. Clinical studies with herpes simplex virus type 2 Curtis strain vaccine.
Corey L
Rev Infect Dis; 1991; 13 Suppl 11():S904-5. PubMed ID: 1664125
[No Abstract] [Full Text] [Related]
14. Efficacy of vaccination with Skinner vaccine towards the prevention of herpes simplex virus induced cervical carcinoma in an experimental mouse model.
Chen MH; Zhou Z; Hartley CE; Cowan M; Skinner GR
Vaccine; 1986 Dec; 4(4):249-52. PubMed ID: 3026107
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial.
Skinner GR; Turyk ME; Benson CA; Wilbanks GD; Heseltine P; Galpin J; Kaufman R; Goldberg L; Hartley CE; Buchan A
Med Microbiol Immunol; 1997 Jun; 186(1):31-6. PubMed ID: 9255764
[TBL] [Abstract][Full Text] [Related]
16. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I
Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus vaccines.
Meignier B; Roizman B
Antiviral Res; 1985; Suppl 1():259-65. PubMed ID: 3002260
[No Abstract] [Full Text] [Related]
18. Herpes vaccine.
Mindel A
Br J Vener Dis; 1984 Jun; 60(3):204-5. PubMed ID: 6329408
[No Abstract] [Full Text] [Related]
19. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.
Skinner GR; Fink C; Melling J; Wiblin C; Thornton B; Hallworth J; Gardner W; McLeish P; Hartley C; Buchan A
Med Microbiol Immunol; 1992; 180(6):305-20. PubMed ID: 1549071
[TBL] [Abstract][Full Text] [Related]
20. New concepts: vaccines.
Rapp F
Gynecol Oncol; 1981 Oct; 12(2 Pt 2):S341-4. PubMed ID: 6273265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
